Drug Trial Radar · NCT03036098
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,314
Actual
Start
Mar 24, 2017
Primary completion
Aug 30, 2024
Study completion Oct 20, 2026
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Ono Pharmaceutical Co., Ltd.
- First posted
- Jan 30, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating participants with previously untreated inoperable or metastatic urothelial cancer.
Conditions
- Urothelial Cancer
Interventions
NivolumabBiological
Specified Dose on Specified Days
IpilimumabBiological
Specified Dose on Specified Days
GemcitabineDrug
Specified Dose on Specified Days
CisplatinDrug
Specified Dose on Specified Days
CarboplatinDrug
Specified Dose on Specified Days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) in Cisplatin-ineligible Randomized Participants for Primary StudyTime frame: From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)
- Overall Survival (OS) in Programmed Death-Ligand 1 (PD-L1) Positive (≥ 1%) Randomized Participants by Immunohistochemistry (IHC) for Primary StudyTime frame: From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)
- Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in Cisplatin-eligible Participants for Sub-studyTime frame: From the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first (up to approximately 89 months)
- Overall Survival (OS) in Cisplatin-eligible Participants for Sub-studyTime frame: From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)
Locations
174 sites in 30 countries. Site status is shown where the registry gives one.
Local Institution - 0001
Anchorage, Alaska
Local Institution - 0115
Fresno, California
St Joseph Heritage Healthcare
Santa Rosa, California
Local Institution - 0051
Boca Raton, Florida
Local Institution - 0087
Fort Lauderdale, Florida
Local Institution - 0062
Jacksonville, Florida
Local Institution - 0004
Athens, Georgia
Local Institution - 0033
Thomasville, Georgia
Local Institution - 0046
Chicago, Illinois
Local Institution - 0117
New Orleans, Louisiana
Local Institution - 0056
Boston, Massachusetts
Local Institution - 0073
Boston, Massachusetts
Local Institution - 0208
Boston, Massachusetts
Local Institution - 0207
Milford, Massachusetts
Local Institution - 0063
Ann Arbor, Michigan
Local Institution - 0002
Burnsville, Minnesota
Hattiesburg Clinic
Hattiesburg, Mississippi
Local Institution - 0032
Kansas City, Missouri
Local Institution - 0095
St Louis, Missouri
Local Institution - 0057
Manchester, New Hampshire
Local Institution - 0084
Albuquerque, New Mexico
Local Institution - 0083
Buffalo, New York
Local Institution - 0014
Mineola, New York
Local Institution - 0072
New York, New York
Local Institution - 0116
Durham, North Carolina
Local Institution - 0082
Columbus, Ohio
Local Institution - 0104
Portland, Oregon
Local Institution - 0013
Pittsburgh, Pennsylvania
Local Institution - 0086
Kirkland, Washington
Local Institution - 0009
Buenos Aires, Argentina
Local Institution - 0134
Córdoba, Argentina
Local Institution - 0006
Córdoba, Argentina
Local Institution - 0008
Viedma, Argentina
Local Institution - 0005
Capital Federal, Buenos Aires, Argentina
Local Institution - 0007
Mar del Plata, Buenos Aires, Argentina
Local Institution - 0096
Waratah, New South Wales, Australia
Local Institution - 0099
Westmead, New South Wales, Australia
Local Institution - 0188
South Brisbane, Queensland, Australia
Local Institution - 0120
Tugun, Queensland, Australia
Local Institution - 0101
Heidelberg, Victoria, Australia
Showing 40 of 174 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.